Hosking Partners LLP grew its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 191,928 shares of the biopharmaceutical company’s stock after acquiring an additional 3,094 shares during the quarter. Hosking Partners LLP’s holdings in Bristol-Myers Squibb were worth $10,694,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Blue Chip Partners Inc. increased its stake in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares during the last quarter. Keel Point LLC increased its stake in shares of Bristol-Myers Squibb by 0.3% during the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 18 shares during the last quarter. Staley Capital Advisers Inc. increased its stake in shares of Bristol-Myers Squibb by 0.3% during the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after acquiring an additional 24 shares during the last quarter. Shayne & CO. LLC increased its stake in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 24 shares during the last quarter. Finally, Greenleaf Trust increased its stake in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 39 shares during the last quarter. 68.97% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Shares Bought by Hosking Partners LLP” was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.truebluetribune.com/2017/11/21/bristol-myers-squibb-company-bmy-shares-bought-by-hosking-partners-llp.html.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company (NYSE BMY) opened at $60.80 on Tuesday. The firm has a market capitalization of $99,510.00, a P/E ratio of 20.72, a price-to-earnings-growth ratio of 2.42 and a beta of 1.18. Bristol-Myers Squibb Company has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 16.29% and a return on equity of 22.99%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.77 earnings per share. equities analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 2.57%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.
A number of research analysts have recently commented on BMY shares. Hilliard Lyons downgraded shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $65.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. SunTrust Banks, Inc. raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price objective for the company in a research note on Wednesday, November 1st. Finally, Barclays PLC boosted their target price on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $64.93.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.